CHICAGO, Oct. 3 /PRNewswire-FirstCall/ -- John Flavin, President of Advanced Life Sciences Holdings, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, respiratory diseases and cancer, is scheduled to present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 8 at The Carlton on Madison Avenue in New York City at 2:15 p.m. Eastern Time.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO )
A live web cast of Mr. Flavin's presentation will be accessible through the Investor Relations page of the Advanced Life Sciences web site, http://www.advancedlifesciences.com. In addition, a replay of the presentation will be available following the presentation and archived on the Company's web site.
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, respiratory diseases and cancer. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections. For more information, please visit us on the web at http://www.advancedlifesciences.com.
Forward-Looking Statements
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Joe Camp, of Advanced Life Sciences, +1-630-754-4352; or Melanie
Nimrodi, +1-312-546-3508, or Kathy Price, +1-213-486-6547, for Advanced
Life Sciences
Web site: http://www.advancedlifesciences.com/
